ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ÐìÁÕ¡¢¡¢Ö£¼ÒÇ¿µÈÕ¹ÏÖ˯ÃßʱÐÍÓëÈÏÖª¹¦Ð§µÄÏ໥¹ØÏµ

¸å¼þȪԴ£º£º£º¹«¹²ÎÀÉúѧԺ ±à¼­£º£º£ºÀîͯÖÛ¡¢¡¢Íõ¶¬Ã· ÉóºË£º£º£ºÖª×ã ÔĶÁÁ¿£º£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Íõ½¿£©È˵ÄÒ»ÉúÖÐÏÕЩÓÐÈý·ÖÖ®Ò»µÄʱ¼äÊÇÔÚ˯ÃßÖжȹýµÄ£¬£¬Ë¯Ãß¶ÔÈËÃǵÄÉíÌ念½¡ºÍ¾«Éñ״̬ÖÁ¹ØÖ÷Òª¡£Ë¯ÃßÖçÒ¹½ÚÂÉÊÇָ˯Ãß-ÐѾõģʽÒÔ24Сʱ×óÓÒΪÖÜÆÚµÄ±ä»»£¬£¬ÓÖ±»³ÆÎªË¯ÃßʱÐÍ£¨chronotype£©£¬£¬¿É·ÖΪÔç˯ÔçÆðµÄ¡°ÇåÔçÐÍ¡±£¨morning-type£©ÓëÍí˯ÍíÆðµÄ¡°Ò¹ÍíÐÍ¡±£¨evening-type£©¡£ËûÃÇÒ²±»ÐÎÏ󵨽Ð×ö¡°°ÙÁéÄñÐÍ¡±£¨¡°larks¡±£©ºÍ¡°Ã¨Í·Ó¥ÐÍ¡±£¨¡°owls¡±£©£¬£¬¶ø´¦ÓÚÖÐÐĵÄÔò±»³ÆÎª¡°ÖÐÐÄÐÍ¡±¡£Í¨³£ÇéÐÎÏ£¬£¬Ôç˯ÔçÆð±»ÒÔΪÊÇ¿µ½¡µÄÉúÑÄϰ¹ß¡£ÔÚÒÔÍùµÄÑо¿ÖУ¬£¬Ïà±ÈÇåÔçÐÍ£¬£¬Ò¹ÍíÐÍÈËȺµÄÒûʳÓëÔ˶¯Ï°¹ß½Ï²î£¬£¬ÇÒÓëÒÖÓô¡¢¡¢·ÊÅÖ¡¢¡¢¸ßѪѹ¡¢¡¢ÌÇÄò²¡¡¢¡¢ÐÄÄÔѪ¹Ü¼²²¡µÈ³£¼ûÂýÐÔ²¡µÄ¹ØÏµ¸üΪÇ×½ü¡£¿ÉÊÇ£¬£¬Íí˯ÍíÆðÊÇ·ñÒ²»áÓ°ÏìÈÏÖª¹¦Ð§Ë®Æ½£¿£¿£¿½áÂÛÉÐÇÒ²»ÇåÎú¡£

¿ËÈÕ£¬£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺÑо¿ÍŶÓÁªºÏÓ¢¹ú²®Ã÷º²´óѧ¡¢¡¢¹ãÖÝÊеÚÊ®¶þÈËÃñÒ½ÔººÍÏã¸Û´óѧµÈÑо¿Ö°Ô±ÅäºÏÔÚ¡¶ÁøÒ¶µ¶¡·×Ó¿¯eClinicalMedicine£¨IF=17.033£©½ÒÏþÌâΪ¡°Chronotype and Cognitive Function: Observational Study and Bidirectional Mendelian Randomization¡±µÄÔ­´´ÐÔÑо¿Ð§¹û£¬£¬½ÓÄɹŰåÊÓ²ìÐÔÑо¿ºÍÃϵ¶ûËæ»ú»¯Á¬ÏµµÄÒªÁ죬£¬Ê×´ÎÉîÈëÕ¹ÏÖÁËÖÐÍíÄêÈË˯ÃßʱÐÍÓëÈÏÖª¹¦Ð§Ë®Æ½µÄÏ໥¹ØÏµ¡£

Ñо¿Ö°Ô±Ê×ÏÈ»ùÓÚ¹ãÖÝÉúÎï¿âÐÐÁпªÕ¹ÁËÒ»ÏîÊÓ²ìÐÔÑо¿¡£¹ãÖÝÉúÎï¿âÐÐÁÐÑо¿£¨Guangzhou Biobank Cohort Study, GBCS£©ÊÇ 2003 ÄêÓɹãÖÝÊеÚÊ®¶þÈËÃñÒ½Ôº¡¢¡¢Ïã¸Û´óѧºÍÓ¢¹ú²®Ã÷º²´óѧÏàÖú¿ªÕ¹µÄÒ»ÏîǰհÐÔÐÐÁÐÑо¿¡£GBCSÓÚ2003~2008Äê¼äÍê³É»ùÏßÊÓ²ìºÍÌå¸ñ¼ì²é£¬£¬¹²ÄÉÈëÁË30,430Ãû50ËêÒÔÉϵĹãÖݳ£×¡×¡Ãñ¡£Í¨¹ý2008-2012ÄêÍøÂçµÄËæ·ÃÊý¾Ý£¬£¬±¾Ñо¿»ùÓÚ14,582Àý¹ãÖÝÖÐÍíÄêÉçÇøÈËȺ¿ªÕ¹¡£¶à±äÁ¿ÏßÐԻعéÆÊÎöЧ¹ûÏÔʾ£¬£¬Ë¯ÃßÖеãºÍÈÏÖª¹¦Ð§ÆÀ·Ö³ÊÕýÏà¹Ø£¬£¬¼´½ÏÍíµÄ˯ÃßÖеãÓë½Ï¸ßµÄÈÏ֪ˮƽÏà¹Ø¡£ÔÚµ÷½âÁËÐԱ𡢡¢ÄêËê¡¢¡¢Éç»á¾­¼Ã״̬¡¢¡¢ÉíÌåÖÊÁ¿Ö¸Êý¡¢¡¢ÉúÑÄ·½Ê½¡¢¡¢¼²²¡Ê·µÈ»ìÔÓÒòËØÒÔºóÏà¹Ø¹ØÏµÒÀÈ»±£´æ (MMSE: ¦Â=0.14; 95% ÖÃÐÅÇø¼ä(CI), 0.09-0.19; DWRT: ¦Â=0.07; 95% CI, 0.04-0.11)¡£

È»¶ø£¬£¬¹Å°åµÄÊÓ²ìÐÔÑо¿ÎÞ·¨¾ÙÐÐÒò¹ûÍÆ¶Ï£¬£¬¹Ê²»¿É¶Ï¶¨´Ë¹ØÁªµÄÆ«Ïò¡£Ñо¿Ö°Ô±½Ó׎ÓÄÉË«ÏòÃϵ¶ûËæ»ú»¯£¨Bidirectional Mendelian randomization, BMR£©Ì½Ë÷˯ÃßʱÐͺÍÈÏÖª¹¦Ð§ÕâÁ½Õß¼äÏ໥ӰÏìµÄÒò¹û¹ØÏµ¡£Ãϵ¶ûËæ»ú»¯£¨MR£©ÊÇÒ»ÖÖʹÓûùÒò±äÒì×÷Ϊ¹¤¾ß±äÁ¿À´ÍƶÏÑо¿ÒòËØ£¨Ë¯ÃßʱÐÍ£©ºÍ¿µ½¡Ï³¡£¨ÈÏÖª¹¦Ð§£©Ö®¼äÒò¹û¹ØÏµµÄÒªÁì¡£ÔÚ»ùÓÚ½ü100ÍòÀýÑо¿Ñù±¾µÄMRÆÊÎöÖУ¬£¬Ñо¿Ö°Ô±·¢Ã÷£¬£¬Ë¯ÃßʱÐͶÔÈÏÖª¹¦Ð§Ã»ÓÐÓ°Ï죬£¬¼´Íí˯²¢²»»á½µµÍÈÏÖª¹¦Ð§¡£Ëæºó£¬£¬Ñо¿Ö°Ô±ÒÔÈÏ֪ˮƽµÄÒÅ´«ÇãÏò×÷ΪÑо¿ÒòËØ£¬£¬À´Ì½Ë÷ÈÏ֪ˮƽ¶ÔÖçÒ¹½ÚÂɱíÐ͵ÄÓ°Ï죬£¬Ð§¹ûÔÚ¶àÖÖMRÆÊÎöÖоùÏÔÊ¾Ëæ×ÅÈÏÖª¹¦Ð§ÆÀ·ÖÉý¸ß£¬£¬Ôç˯µÄ¸ÅÂÊÒ²ËæÖ®½µµÍ (UK Biobank: OR=0.88; 95% CI, 0.83-0.93; 23andMe: 0.87; 95% CI, 0.80-0.95)¡£


4D0C3C63C9BC577F15694EEDBDA_BE1DCF3F_B735

ͼ1. ±¾Ñо¿Éè¼ÆÓëÖ÷ҪЧ¹û


ÏÖÔÚ£¬£¬Ë¯ÃßʱÐÍÓëÈÏÖª¹¦Ð§Ö®¼äµÄ¹ØÏµÔÚ²î±ðµÄÑо¿Öв¢·×ÆçÖ¡£ÀýÈ磬£¬ÒÔÍùÑо¿·¢Ã÷ÔÚ¶ùͯºÍÇàÉÙÄêÖÐÍí˯ÓëÈÏ֪ˮƽ½ÏµÍÓйØ£¬£¬¶øÔÚÖÐÍíÄêÈËÖÐÔò·¢Ã÷Íí˯ÓëÈÏ֪ˮƽ½Ï¸ßÓйØ¡£ÕâÖÖЧ¹ûµÄÇø±ðÓпÉÄÜÊÇÓÉÓÚ¶ùͯºÍÇàÉÙÄêÓÐ׎ÏΪÑÏ¿áµÄ×÷Ϣʱ¼äºÍ¸ü¶àµÄ˯ÃßÐèÇ󣬣¬Íí˯¿ÉÔì³É×Ü˯Ãßʱ³¤ïÔÌ­£¬£¬´Ó¶ø¼ä½ÓÓ°ÏìÁËÈÏÖª¹¦Ð§¡£¶øÔÚ±¾Ñо¿ÄÉÈëµÄ¹ãÖÝÉúÎï¿âÐÐÁÐÖУ¬£¬³¬99%µÄ¼ÓÈëÕßΪÒÑÍËÐݵÄÍíÄêÈË£¬£¬Í¨¹ýÏÖʵ˯ÃßÖеãÍÆ²âµÄʱÐÍÔò·´Ó³ÁËÌåÄÚÕæÊµµÄ˯Ã߯«ºÃ¡£±ðµÄ£¬£¬Ñо¿½ÓÄÉ»ùÓÚ´óÑù×Ô¼ºÈºÊý¾Ý¿ªÕ¹MRÆÊÎö£¬£¬¿Éɨ³ý¹Å°åÊÓ²ìÐÔÑо¿ÖÐÍùÍùÎÞ·¨×èÖ¹µÄ»ìÔÓÆ«ÒУ¬£¬ÓÐÖúÓÚÆÊÎö˯ÃßʱÐͺÍÈÏÖª¹¦Ð§µÄÏ໥¹ØÏµ¡£

×ÜÖ®£¬£¬Õë¶Ô¡°Íí˯¡±ÕâÒ»±»¹«¹²ÆÕ±é¹Ø×¢µÄ˯ÃßÌØÕ÷£¬£¬±¾Ñо¿Ê״δÓÈËȺ²ãÃæºÍ»ùÒò²ãÃæÖ¤ÊµÁËÍí˯²¢²»»áÓ°ÏìÈÏÖª¹¦Ð§£¬£¬Ïà·´µÄ£¬£¬½Ï¸ßµÄÈÏÖª¹¦Ð§Ë®Æ½»áÔöÌíÍí˯µÄ¸ÅÂÊ¡£¹ØÓÚÓС°Íí˯¡±Ï°¹ßµÄÖÐÍíÄêÈ˶øÑÔ£¬£¬ËûÃǿɲ»±Øµ£ÐÄ˯µÃÍí»áµ¼ÖÂÈÏÖª¹¦Ð§Ï½µ¡£Ñо¿Ð§¹ûÒ²ÓÐÖúÓÚ½øÒ»²½Ã÷È·ÈÏÖª¹¦Ð§µÄÓ°ÏìÒòËØºÍ˯ÃßʱÐͶԿµ½¡µÄÓ°Ïì¡£

ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ²©Ê¿ºóÍõ½¿ºÍ˶ʿÉúÀèÓ°ÈçΪÂÛÎÄÅäºÏµÚÒ»×÷Õߣ¬£¬ÐìÁÕ½ÌÊÚºÍÖ£¼ÒÇ¿½ÌÊÚΪÅäºÏͨѶ×÷Õß¡£ÂÛÎĵÚÒ»µ¥Î»Îªngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ¡£¸ÃÑо¿Êܹú¼Ò×ÔÈ»¿ÆÑ§»ù½ð£¨No. 82103930£©£¬£¬¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ð£¨No. 2022A1515011546£©µÈÏîÄ¿µÄ×ÊÖú¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://authors.elsevier.com/sd/article/S2589-5370(22)00443-6

¡¾ÍøÕ¾µØÍ¼¡¿